1. Scrip
  2. >>Business

‘Anti-VEGFs Have Reached Their Limit:’ EyeBio Targets New Pathway For Eye Therapies

Potential First-In-Class Wnt Agonist

 
• By Andrew McConaghie

Led by the duo who brought the first anti-VEGF drug to market, EyeBio aims to develop the next breakthrough eye therapy via a novel tri-specific antibody.

Around half of patients taking anti-VEGF therapies still have fluid on the eye, compromising their vision. • Source: Image archive

Eyebio, the company launched last year by two ophthalmology drug development veterans, believes it can surpass the benefits of existing anti-VEGF blockbusters with its pipeline of multi-specific agonist antibodies.

Co-founded by former Roche ophthalmology research leader Tony Adamis and ex-CEO of retinal diseases biotech Iveric Bio David Guyer, EyeBio has now unveiled its lead candidate Restoret, a tri-specific Wnt agonist antibody, and the co-founders told Scrip

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.